These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 33837614)
1. Humoral immune responses to AAV gene therapy in the ocular compartment. Whitehead M; Osborne A; Yu-Wai-Man P; Martin K Biol Rev Camb Philos Soc; 2021 Aug; 96(4):1616-1644. PubMed ID: 33837614 [TBL] [Abstract][Full Text] [Related]
2. Strategies to circumvent humoral immunity to adeno-associated viral vectors. Tse LV; Moller-Tank S; Asokan A Expert Opin Biol Ther; 2015 Jun; 15(6):845-55. PubMed ID: 25985812 [TBL] [Abstract][Full Text] [Related]
3. Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients. Gross DA; Tedesco N; Leborgne C; Ronzitti G Front Immunol; 2022; 13():857276. PubMed ID: 35464422 [TBL] [Abstract][Full Text] [Related]
4. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696 [TBL] [Abstract][Full Text] [Related]
5. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer. Costa Verdera H; Kuranda K; Mingozzi F Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays. Gorovits B; Azadeh M; Buchlis G; Harrison T; Havert M; Jawa V; Long B; McNally J; Milton M; Nelson R; O'Dell M; Richards K; Vettermann C; Wu B AAPS J; 2021 Sep; 23(6):108. PubMed ID: 34529177 [TBL] [Abstract][Full Text] [Related]
7. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574 [TBL] [Abstract][Full Text] [Related]
15. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion. Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965 [TBL] [Abstract][Full Text] [Related]
16. Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood. Smith CJ; Ross N; Kamal A; Kim KY; Kropf E; Deschatelets P; Francois C; Quinn WJ; Singh I; Majowicz A; Mingozzi F; Kuranda K Front Immunol; 2022; 13():999021. PubMed ID: 36189251 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy. Gorovits B; Azadeh M; Buchlis G; Fiscella M; Harrison T; Havert M; Janetzki S; Jawa V; Long B; Mahnke YD; McDermott A; Milton M; Nelson R; Vettermann C; Wu B AAPS J; 2023 Apr; 25(3):47. PubMed ID: 37101079 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients. Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923 [TBL] [Abstract][Full Text] [Related]
19. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies. Lotfinia M; Abdollahpour-Alitappeh M; Hatami B; Zali MR; Karimipoor M Clin Exp Med; 2019 Aug; 19(3):289-298. PubMed ID: 31054018 [TBL] [Abstract][Full Text] [Related]
20. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Grimm D; Kay MA Curr Gene Ther; 2003 Aug; 3(4):281-304. PubMed ID: 12871018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]